In the specialized field of biochemical research, the exploration of protein complexes requires precise tools. As someone who follows advancements in peptide science, I have found that the latency associated peptide antibody is a critical component for researchers investigating the complex regulatory mechan by F Lambert · 2025 — The resulting LAP and mature TGF-β1 homodimers remain non-covalently associated, forming a complex called “latent TGF-β1” because LAP prevents isms of cytokines. Understanding how these tools function helps clarify the complex structural biology of the transforming growth factor-beta (TGF-β) superfamily.
The Biological Context of Latency Associated Peptide
To appreciate the utility of a specific antibody, one must first look at the target. The latency associated peptide (LAP) is an 80-kDa protein that serves as a fundamental component of the latent TGF-β complex. My review of the literature suggests that TGF-β is synthesized as a large protein precursor and then secreted as a complex of TGF-β and LAP, in which LAP noncovalently associates with the mature cytokine.
A key detail in this process is that the TGF-β propeptide is covalently bound through disulphide bonds in the endoplasmic reticulum. Furthermore, TGF-beta 1 is expressed as a proprotein that is cleaved within the trans-Golgi to yield the LAP and the mature TGF-beta 1 homodimers. These elements remain associated, forming a "latent" complex because the LAP physically prevents the cytokine from binding to its receptors.
Research Applications and Antibody Specificity
Researchers often utilize various monoclonal antibodies to study these structures. For instance, the VB3A9 monoclonal antibody is frequently cited for its ability to recognize human LAP. Similarly, other tools like the TW4-2F8 or TW7-16B4 monoclonal antibodies are used to react with mouse latency associated peptide.
When selecting an antibody for experimental workflows, researchers look for high specificity. Some s PE anti-human LAP (TGF-β1) Antibody tudies focus on an antibody that specifically bound to the latent form of TGF-β1 presented i Description: The TW7-16B4 monoclonal antibody reacts with mouse latency associated peptide (LAP, pro-TGF beta 1, LAP/TGF beta 1). Many different cells produce n the extracellular matrix, effectively preventing its release. The anti-LAP antibody which targets the latency-associated peptide (LAP)/TGF-β complex on Tregs and other cells has become a significant interest for those studying immune regulation in vitro and in vivo.
Structural Insights and Technical Considerations
The structural integrity of these complexes is fascinating. It is well-documented that TGF-β is released from degranulating platelets and secreted from nearly all cells in a biologically inactive state. The LAP is a component of the latent complex of TGF-β, which is often disulphide-linked to a protein called LTBP (latent TGF-β binding protein).
For those conducting laboratory assays, it is helpful to note:
* Conformational Switchin This VB3A9 monoclonal antibody recognizes human latency-associated peptide (LAP), also known as the TGF-beta propeptide. g: Structural studies have identified how the peptide switches between bound and unbound states.
* R The Activation Sequence of Thrombospondin-1 Interacts ecombinant TGF-β is synthesized as a large protein precursor and then secreted as a complex of TGF-β and LAP (latency-associated peptide), in which LAP noncovalently Options: Recombinant truncated latency-associated peptide has been utilized in studies to observe impacts on cellular pathways, such as the TGF-β/Smad pathway.
* Diversity of Tools: Whether you are looking by SMF Ribeiro · 1999 · Cited by 473 — We now report that the latency-associated peptide (LAP) of the latent TGF-β complex also interacts with thrombospondin-1 as part of a biologically active for a human LAP (TGF-β1) antibody or seeking to understand the latency mechanisms, the availability of validated antibodies is essential for consistent data.
Conclusion
The study of the latency associated peptide and the corresponding peptide research tools continues to evolve. By utilizing specific monoclonal antibodies, scientists can gain deeper insights into how the associated proteins regulate cytokine availability. Whether the focus is on the latency of the complex or the specific associated peptide interactions, these laboratory reagents remain foundational for anyone working with the TGF-β pathway. As research progresses, the ability to isolate and target these specific protein regions will undoubtedly yield further advancements in our understanding of cellular signaling.